Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 6, 2008, Pages 2042-2049

  Shahani, Sadeka ^a   Braga Basaria, Milena ^b   Basaria, Shehzad ^c  

^a HARBOR HOSPITAL   (United States)

^b Johns Hopkins University School of Medicine ^*

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ANDROGEN; APOLIPOPROTEIN B; FLUTAMIDE; GLUCOSE; GONADORELIN; GONADORELIN AGONIST; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; STATIN; TESTOSTERONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADJUVANT THERAPY; ATHEROSCLEROSIS; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 45149116659     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2595     Document Type: Review

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ 2007 Cancer statistics, 2007. CA Cancer J Clin 57:43-66
2. Huggins C, Stevens Jr RE, Hodges CV 1941 Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209-223
3. Smith MR 2007 Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 14:247-254
4. Chodak GW, Keane T, Klotz L 2002 Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60:201-208
5. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D 1999 Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788
6. Sharifi N, Gulley JL, Dahut WL 2005 Androgen deprivation therapy for prostate cancer. JAMA 294:238-244
7. Chodak GW 1998 Comparing treatments for localized prostate cancer: persisting uncertainty. JAMA 280:1008-1010
8. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS 2005 Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:1615-1624
9. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G 1999 Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467
10. Basaria S, Dobs AS 2001 Hypogonadism and androgen replacement therapy in elderly men. Am J Med. 110:563-572
11. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L 1996 Low levels of sex hormone-binding globulin and testosterone predict the development of noninsulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 143:889-897
12. Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT 2005 Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 90:2618-2623
13. Satariano WA, Ragland KE, van den Eeden SK 1998 Cause of death in men diagnosed with prostate carcinoma. Cancer 83:1180-1188
14. Lu-Yao G, Stukel TA, Yao SL 2004 Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 171:2285-2290
15. Basaria S, Wahlstrom JT, Dobs AS 2001 Anabolic-androgenic steroid therapy in the treatment of chronic diseases. J Clin Endocrinol Metab 86:5108-5117
16. Basaria S, Lieb 2nd J, Tang A, DeWeese T, Carducci M, Eisenberger M, Dobs AS 2002 Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 56:779-786
17. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS 2001 The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261-4267
18. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW 2002 Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603
19. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL 2002 Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 95:2136-2144
20. Lee H, McGovern K, Finkelstein J, Smith MR 2005 Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104:1633-1637
21. Haffner SM, Valdez RA, Mykkanen L, Stern MP, Katz MS 1994 Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 43:599-603
22. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT 2004 Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036-1041
23. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ 2005 Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90:2636-2641
24. Marin P, Holmang S, Jonsson L, Sjöström L, Kvist H, Holm G, Lindstedt G, Björntorp P 1992 The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16:991-997
25. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C 2003 Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104:195-201
26. Smith MR, Lee H, Nathan DM 2006 Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91:1305-1308
27. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS 2006 Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer 106:581-588
28. Keating NL, O'Malley AJ, Smith MR 2006 Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-4456
29. Garnick MB, Pratt CM, Campion M, Shipley J 2004 The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. J Clin Oncol 22:4578
30. Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, Straub RH 2004 Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 13:635-638
31. Hotamisligil GS, Spiegelman BM 1994 Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 43:1271-1278
32. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults 2001 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
33. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S 2006 Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24:3979-3983
34. Haffner SM, Mykkanen L, Valdez RA, Katz MS 1993 Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 77:1610-1615
35. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH 2004 The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89:3313-3318
36. Moorjani S, Dupont A, Labrie F, Lupien PJ, Gagné C, Brun D, Giguère M, Bélanger A, Cusan L 1988 Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab 66:314-322
37. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S 2006 Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 18:494-498
38. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS 2007 Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:1493-1500
39. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW 2007 Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420-2425
40. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR 2007 Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524